Themes / Group
Active · newly observed relationshipLatest completed snapshot · 16:55 ET

MARKET-DISCOVERED GROUP

Drug Manufacturers - General

THE TRADER READShared activity without a clean directional read

Price direction is split across 13 measured members. Capital-flow confirmation is unavailable.

Price breadth12 up · 1 downRelative median unavailable
Capital-flow alignmentUnavailablePrice breadth is not yet confirmed by flow
Activity nowBuilding_pressureActivity score 43/100
Evidence depth0 support daysLow sample—context, not a validated playbook
EVIDENCE CLOCK

What happened, in timestamp order

1 timed event
TIMING READA causal timing read is unavailable because no material member price onset could be timestamped.
2 earlier filing context receipts

TUE, APR 28BIIB filing documented shared operating contextdemand / volume · date precision only

THU, MAY 7ABBV filing documented shared operating contextdemand / volume · date precision only

Headline times and retained activity confirmations are point-in-time evidence. Price order is inferred from aligned 5-minute bars. Filing evidence has date precision only and is context, not an intraday catalyst claim.

01 · WHAT IS HAPPENING

The move, the flow and who is driving it

Price breadth, unusual activity and signed capital flow are separate observations
Price sequence unavailableA timestamped price sequence is unavailable.
RELATIVE CO-MOVEMENT

How the members are behaving together

Session-normalized

Observed intraday paths are not available for this group yet.

02 · WHY IT MATTERS

Why now and where the move could travel

Context and lead/lag links are evidence, not proof of causation or a forecast
WHY THIS GROUP EXISTS

Shared filing context

11/13 members covered

Moderate filing support: the strongest shared 10-Q/K outlook is operating setup (near-term outlook) across BIIB, BMY, HCA, MRK, REGN, RPRX, THC, UHS, VRTX.

demand / volume

“AbbVie's global Imbruvica revenues decreased 25% for the three months ended March 31, 2026 primarily driven by unfavorable pricing and decreased demand in the United States, partially offset by increased collaboration revenues.”

ABBV 10-Q · 2026-05-08
demand / volume affecting revenue

“Increases in demand on any of AbbVie's suppliers could result in delays and disruptions in the manufacturing, distribution and sale of its products and/or product shortages, leading to lost revenue.”

ABBV 10-K · 2026-02-20
credit / rates affecting interest expense

“Other Non-Operating Expenses years ended December 31 (in millions) 2025 2024 2023 Interest expense $ 2,893 $ 2,808 $ 2,224 Interest income (266) (648) (540) Interest expense, net $ 2,627 $ 2,160 $ 1,684 Net foreign exchange loss $ 58 $ 21 $ 146 Other expense, net 5,793 3,240 4,677 Interest expense in 2025 increased compared to 2024 primarily due to the impact of higher effective interest rates.”

ABBV 10-K · 2026-02-20
CONFIRMATION NETWORK

Outsiders and cross-asset links

0 outsiders confirming
ABBV → UVXYPositive historical lead/lag · strength 0.27
ABBV → SLVInverse historical lead/lag · strength -0.16

Filing-linked outsiders test whether the move is spreading beyond the established cohort.

No high-confidence filing-linked outsiders are available for this group yet.

03 · WHO IS IN IT

Member participation

Unusual activity and daily price direction are shown separately
ABBVTHCAMGNMRKUHSRPRXVRTXSNYGSKREGNHCABIIBBMY

11/13 active12 rising · 1 falling

MemberUnusual activityToday's moveRead now
ABBVAbbVie Inc.
Most unusual · 100/100
+3.4%
Active; unclassifiedHistorical role unavailable
THCTenet Healthcare Corporation
Elevated · 88/100
+2.2%
Active; unclassifiedHistorical role unavailable
AMGNAmgen Inc.
Elevated · 78/100
+1.4%
Active; unclassifiedHistorical role unavailable
MRKMerck & Company, Inc.
Elevated · 78/100
-0.6%
Active; unclassifiedHistorical role unavailable
UHSUniversal Health Services, Inc.
Elevated · 77/100
+1.4%
Active; unclassifiedHistorical role unavailable
RPRXRoyalty Pharma plc
Elevated · 76/100
+0.4%
Active; unclassifiedHistorical role unavailable
VRTXVertex Pharmaceuticals Incorporated
Elevated · 75/100
+2.4%
Active; unclassifiedHistorical role unavailable
SNYSanofi
Elevated · 74/100
+1.2%
Active; unclassifiedHistorical role unavailable
GSKGSK plc
Elevated · 73/100
+1.7%
Active; unclassifiedHistorical role unavailable
REGNRegeneron Pharmaceuticals, Inc.
Elevated · 73/100
+0.5%
Active; unclassifiedHistorical role unavailable
HCAHCA Healthcare, Inc.
Elevated · 71/100
+1.6%
Active; unclassifiedHistorical role unavailable
BIIBBiogen Inc.
Elevated · 68/100
+1.8%
Active; unclassifiedHistorical role unavailable
BMYBristol-Myers Squibb Company
Elevated · 67/100
+2.2%
Active; unclassifiedHistorical role unavailable
View exact member values
TICKERCompanyRole nowTodayObserved historyTrader interpretation
ABBVAbbVie Inc.Most unusual+3.4%—Most unusual activity in this snapshot; performance direction may differ.
THCTenet Healthcare CorporationParticipating+2.2%—Price participation is not yet confirmed by per-name flow.
AMGNAmgen Inc.Participating+1.4%—Price participation is not yet confirmed by per-name flow.
MRKMerck & Company, Inc.Participating-0.6%—Price participation is not yet confirmed by per-name flow.
UHSUniversal Health Services, Inc.Participating+1.4%—Price participation is not yet confirmed by per-name flow.
RPRXRoyalty Pharma plcParticipating+0.4%—Price participation is not yet confirmed by per-name flow.
VRTXVertex Pharmaceuticals IncorporatedParticipating+2.4%—Price participation is not yet confirmed by per-name flow.
SNYSanofiParticipating+1.2%—Price participation is not yet confirmed by per-name flow.
GSKGSK plcParticipating+1.7%—Price participation is not yet confirmed by per-name flow.
REGNRegeneron Pharmaceuticals, Inc.Participating+0.5%—Price participation is not yet confirmed by per-name flow.
HCAHCA Healthcare, Inc.Participating+1.6%—Price participation is not yet confirmed by per-name flow.
BIIBBiogen Inc.Participating+1.8%—Price participation is not yet confirmed by per-name flow.
BMYBristol-Myers Squibb CompanyParticipating+2.2%—Price participation is not yet confirmed by per-name flow.

04 · HAS THIS HAPPENED BEFORE

Identity history versus measured outcomes

Structural recurrence is not the same as a validated trading outcome
POINT-IN-TIME LIVE OUTCOMES

Live outcome ledger collecting

0/0 events completed

No completed point-in-time outcome is available yet. New live confirmations are now retained with their exact observation timestamp; statistics appear only after the corresponding candles complete.

No point-in-time live observations have completed yet.
Low structural sample

Only 0 completed episodes across 0 active sessions; treat history as context, not a validated playbook. These episode counts describe recurrence; the outcome ledger above is the only forward-performance evidence.

Structural support0 daysHow often the cohort identity was observed
Completed episodes0Separate periods of broad group activity
Active sessions0Completed session observations, not trades

Historical cohort observations are not available yet.